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Abstract
Screening and treatment of hypertension is a cornerstone of cardiovascular disease
(CVD) prevention. Hypertension causes a large proportion of cases of stroke, coronary
heart disease, heart failure, and associated disability and is highly prevalent especially
among older adults. On the one hand, there is robust evidence that screening and
treatment of hypertension prevents CVD and decreases mortality in the middle-aged
population. On the other hand, among older adults, observational studies have
shown either positive, negative, or no correlation between blood pressure (BP)
and cardiovascular outcomes. Furthermore, there is a lack of high quality evidence for a
favorable harm-benefit balance of antihypertensive treatment among older adults,
especially among the oldest-old (i.e., above the age of 80 years), because very few
trials have been conducted in this population. The optimal target BP may be higher
among older treated hypertensive patients than among middle-aged. In addition,
among frail or multimorbid older individuals, a relatively low BP may be associated
with worse outcomes, and antihypertensive treatment may cause more harm than
benefit. To guide hypertension screening and treatment recommendations among
older patients, additional studies are needed to determine the most efficient screening
strategies, to evaluate the effect of lowering BP on CVD risk and on mortality, to determine
the optimal target BP, and to better understand the relationship between BP,
frailty, multimorbidity, and health outcomes.
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Background
Screening and treatment of hypertension is a cornerstone of the prevention of cardiovascu-
lar disease (CVD), which is the leading cause of death and hospitalization worldwide [1].
Hypertension causes a large proportion of stroke, coronary heart disease, heart failure, and
associated disability [2]. Currently, one quarter to one third of the adult population in the
USA and in European countries have hypertension [3, 4]. Because blood pressure (BP) in-
creases with age [5], and as a result of population aging [1], the prevalence of hypertension
is expected to increase in the coming decades and a rapidly growing number of older adults
will have to be managed for hypertension. This constitutes a true public health challenge
for healthcare providers, who are in need of evidence-based clinical guidance.
While there is high quality evidence to guide screening and treatment of hyperten-
sion for the prevention of CVD in middle-aged adults, little evidence exists among
older adults. Few trials have been conducted in this population [6–9], especially among
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the oldest-old, i.e., aged above 80 years. Further, there are conflicting observations
about the relationship between BP and health outcomes among older adults, some
cohort studies having shown that low BP could be detrimental especially among the
oldest frail or multimorbid adults [10, 11].
In this review, we aimed to critically appraise evidence and guidelines for screen-
ing and treatment of hypertension in older patients, with an emphasis on the
oldest-old, multimorbid, and frail patients. Due to the broadness of the field, we did
not conduct a systematic review, better designed to address relatively narrow re-
search questions, and rather preferred to conduct a narrative review, better suited
to provide interpretation and critique of evidence [12]. First, we looked for data on
how BP and hypertension relate to age, health outcomes, and mortality among older
individuals. Second, we searched for experimental and observational evidence on
the relationship between BP, antihypertensive treatments, and health outcomes in
older adults, accounting for different health status, notably for frailty [13]. Finally,
we critically appraised recommendations from major hypertension management
guidelines for older adults.
Epidemiology of blood pressure and hypertension-related mortality across ages
BP increases steadily with age [5], and consequently, the prevalence of hypertension is
higher in older age groups [14]. Hypertension is diagnosed by sustained elevated BP, with
a threshold usually set at 140/90 mmHg (based on office measurement) [6–9], although
recent guidelines set the diagnostic threshold at lower BP levels [15]. In the USA and in
Fig. 1 Mean SBP and DBP according to age. The data was extracted from the National Health and Nutrition
Examination Survey held in the USA between 2013 and 2014. Source: Centers for Disease Control and
Prevention [18, 68]
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European countries, one quarter to one third of the general population would have
hypertension [3, 4]. Many epidemiologic studies have shown that systolic blood
pressure (SBP) increases with age while diastolic blood pressure (DBP) increases up
the age of 60–70 years and decreases with older age (Fig. 1) [16, 17]. In some coun-
tries, up to 75% of older adults are hypertensive [3, 14, 18] (Fig. 2). Middle-aged
adults most often develop systolo-diastolic hypertension, whereas older adults de-
velop predominantly isolated systolic hypertension (defined as SBP ≥ 140 mmHg
and a DBP < 90 mmHg) [19].
Hypertension is a major cause of CVD and mortality [20]. A large meta-analysis in-
cluding 61 prospective studies and analyzing data from one million adults aged between
40 and 89 years demonstrated a strong positive log-linear relationship between BP and
both cardiovascular and all-cause mortality across all age groups [5, 21]. Further, in all
age groups, the risk was the lowest at 115/75 mmHg [5]. A log-linear relationship
between BP and cardiovascular health outcomes was also observed in several other
studies [21–23]. A key to better understand the relationship between BP and health
outcomes among older adults is to account for the very high absolute risk of CVD in
this population [21, 23]. This means that among older adults, a BP difference of
10 mmHg, for instance, is associated with a much larger difference in absolute risk of
CVD compared to the same BP difference among younger adults [5]. Consequently, the
potential absolute benefit of reducing BP could be much higher among older adults,
and more so among oldest-old patients. The relationship between BP and cardiovascu-
lar health outcomes is however much more complex among the oldest-old, as discussed
in detail below.
Measurement of blood pressure and screening for hypertension in older adults
Methods of BP measurement in older adults are roughly similar to the methods in mid-
dle-aged adults, but closer monitoring is recommended by several guidelines [6, 8, 15],
Fig. 2 Hypertension prevalence according to sex in the USA over the years 2011 to 2014. The data was
extracted from the National Health and Nutrition Examination Survey held in the USA between 2011 and
2014. Source: Centers for Disease and Prevention [14]
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especially because older adults tend to have higher BP variability [24]. Older adults also have
more frequently isolated systolic hypertension [19]. In the office, BP is measured tradition-
ally on the upper arm using either the auscultatory method (requiring adequate training of
the assessor) or the oscillometric method (requiring a clinically validated automated meas-
urement device) [8]. To diagnose hypertension, repeated BP measurements at multiple visits
are needed. Out-of-office measurements, either using ambulatory BP monitoring (ABPM)
or home BP monitoring (HBPM) [7, 8], are recommended to confirm diagnoses of hyper-
tension, especially in older adults. Orthostatic hypotension is frequent among older adults,
with up to 30% among those aged more than 70 years old, and can seriously complicate
treatment of hypertension [25, 26]. Recent guidelines recommend searching systematically
for orthostatic hypotension in older individuals [8].
Screening for hypertension is justified for several reasons. In general, screening aims
to distinguish apparently healthy persons who probably have a disease from those who
probably do not [27]. In the case of hypertension, screening aims to identify individuals
with sustained elevated BP and who would benefit from treatment through a reduction
in CVD risk. According to the Wilson and Jungner criteria [27], screening for hyperten-
sion in older adults can be easily justified (Table 1) because hypertension is highly
Table 1 Selected Wilson and Jungner screening criteria adapted to hypertension screening in
older adults [27]
Criterion Criterion related to older adults
The condition sought should be an
important health problem
Hypertension CVD and the absolute risk associated
with elevated BP in older adults is very high.
Hypertension is highly prevalent in the general
population and the prevalence increases with
age (reaching up to 75% among adults aged
75 years and more).
There should be an accepted treatment
for patients with recognized disease
Treatments are accessible and have been shown
to be effective among middle-aged adults. The
evidence among older adults is much weaker.
In frail or multimorbid patients, lowering BP
could cause harm [10].
Facilities for diagnosis and treatment
should be available
Screening and diagnosis are usually done by
primary care physicians. Screening can also be
done out of the office, e.g., by pharmacists [69].
Due to the growing number of older adults,
provision of treatment will require growing
resources, i.e., primary care physicians and
other health professionals. To improve
hypertension control, novel approaches to
care are needed, e.g., team-based care [70].
There should be a recognizable latent
or early symptomatic stage
Elevated BP is a causal risk factor for CVD.
However, the discriminative power of BP
measurement between high- and low-risk
patients is weak [28]. Accordingly, other
factors such as age and history of CVD are
suggested to be more efficient for the
assessment of the risk to develop CVD.
There should be a suitable test or examination Auscultatory or oscillometric methods can be
used. For the auscultatory method, training
is necessary. For the oscillometric method,
a clinically validated device should be used.
The test should be acceptable to the population BP measurement is well accepted among
older adults.
The natural history of the condition, including
development from latent to declared disease,
should be adequately understood
The relationship between BP and cardiovascular
outcomes are not clearly defined in older adults,
especially in frail or multimorbid older adults.
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prevalent and causes serious health issues, BP measurement is relatively simple,
accessible and acceptable for older adults, and treatments are available and efficient
to lower BP.
There are however two major issues with hypertension screening in older adults. A
first issue is the weak discriminative power of elevated BP for having or not CVD later
in life [28]. While individuals with elevated BP have a higher relative risk of CVD, many
cases of CVD will occur in individuals with normal BP. This is especially problematic
for patients with BP close to the threshold above which a treatment is recommended,
and many older adults have BP close to such threshold. To overcome this issue, two
approaches are possible. The first approach is a high-CVD risk prevention strategy,
where the decision to treat hypertension is not based on BP level, but rather on an esti-
mated absolute CVD risk [29]. The idea is that, for the same BP reduction, the absolute
benefit will be much higher among patients at high absolute CVD risk compared with
patients at relatively low absolute CVD risk. In a simulation study, Karmali et al. deter-
mined that a treatment strategy based on absolute CVD risk would reduce the propor-
tion of treated individuals by 29%, while preventing 16% more events for the same
number of persons treated, compared to a treatment strategy based on treating everyone
with SBP higher than 150 mmHg [30]. The second approach would be a population-based
prevention strategy shifting the distribution of BP toward lower levels in the entire popula-
tion, instead of lowering BP only in high-risk populations with high BP or high risk
of CVD [23, 31].
Apart from the weak discriminative power of elevated BP, a second issue with BP
screening among older adults is that the benefit of lowering BP among the oldest-old is
disputable. While these patients are at very high risk for CVD, there are doubts about a
true benefit of BP lowering drugs on mortality and other health outcomes. Instead of
being beneficial, a low BP might indeed be detrimental among oldest-old patients [10].
Blood pressure and related outcomes: evidence from trials and cohort studies
in oldest-old adults
The relationship between BP and mortality and other health outcomes in older age and
the decision to treat or not oldest-old adults for hypertension is highly debated. In
middle-aged adults, the risk for cardiovascular events, cardiovascular mortality, and
all-cause mortality increases with increasing BP [5]. Likewise, numerous trials in
middle-aged adults [32–35], and others like SHEP [36] and Syst-Eur [37], which en-
rolled participants 60 years and over, have shown that lowering BP with antihyperten-
sive treatment reduces mortality and CVD risk.
In oldest-old adults, however, evidence about the predictive value of BP and the
benefit-harm balance of treating hypertension is inconsistent [6–9]. On the one hand,
two randomized controlled trials (RCTs)—SPRINT and HYVET—targeting older pa-
tients aged respectively 75 and 80 years old and over have shown the benefits of lower-
ing BP by reducing mortality and CVD risk [38, 39]. On the other hand, several cohort
studies of adults 80 years of age and over have shown that participants with low BP at
baseline had higher all-cause mortality rates [40–50]. These findings suggest that lower-
ing BP among the oldest-old might be harmful. Table 2 presents a detailed overview of
these studies. Several cohort studies have also shown that low BP was associated with a
decline in cognitive and physical abilities [51–54].
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Several reasons could explain the discrepancies between the results from trials and
from cohort studies, that is, (1) effect modification by frailty or other indicators of poor
health, (2) confounding and reverse causality, and (3) selection of patients in trials (Table 3).
First, the association between BP and CVD risk may be modified by poor health, such
as frailty [11]. Frailty is a multidimensional geriatric syndrome characterized by in-
creased vulnerability and loss of adaptability to stress [55–57] (Table 4). For instance,
in a study by Van Hateren et al., frail participants with high BP had lower all-cause
mortality rates than frail participants with low BP [58]. In another study by Odden et
al. walking speed—used as a frailty indicator—modified the association between BP and
the risk of CVD [59]. Among slow walkers, high BP was not associated with higher car-
diovascular mortality rates, while high BP was associated with higher CVD mortality
Table 3 Hypotheses on discrepancies between cohort studies and RCTs
Hypotheses Description
Effect modification of the relationship
between BP and health outcomes by
frailty or other indicators of poor health
The predictive effect of BP on mortality and adverse health
outcomes might be reversed by age-related frailty or other
indicators of poor health (e.g., multimorbidity) [11]. Several
cohort studies, which enrolled participants aged 60 years
and over, have found that participants with no indicators
of poor health with high BP had higher mortality rates and
worse health outcomes, while participants with indicators
of poor health with high BP had lower mortality rates and
better health outcomes. The association may be modified
by frailty [58, 59], limitations in cognitive and physical
functioning [45, 48], and multimorbidity [49].
Confounding and reverse causality Confounding: the relationship can be confounded by
unmeasured factors, which have an effect on both BP and
the risk of adverse health outcomes. Reverse causality:
some conditions, which can be initially caused by high
BP, evolve to become the cause of low BP [42].
Patient selection in clinical trials RCTs might select participants in better health, with fewer
comorbidities, and with a longer life expectancy than
participants in population-based cohort studies, with the
latter being more representative of the general population.
For instance, HYVET and SPRINT trials have well-defined
and restrictive eligibility criteria for participants, who are
healthier than the general population of the same age
[10]. Post-randomization confounding may also bias results
of trials [62].
Table 4 Definition of frailty
General definition
Frailty is a multidimensional geriatric syndrome characterized by an increased vulnerability and a loss of
adaptability to stress. This state is characterized by an increased risk of adverse outcomes, such as falls, delirium,
disability, and mortality [55, 57, 71]. Two main models allow to assess the frailty status of patients: Fried’s
phenotype model and Rockwood’s cumulative deficit model.
Fried’s phenotype model
A frailty phenotype is based on the five following features:
• Unintentional weight loss
• Self-reported exhaustion
• Low energy expenditure
• Slow gait speed
• Weak grip strength
Patients with none of these features are considered as not frail (or robust), those with one or two as pre-frail,
and those with three or more as frail [13].
Rockwood’s cumulative deficit model
Frailty is defined as an accumulation of defined individual deficits, where the more of these deficits a person
has, the higher the probability that this person is frail. Accordingly, a “frailty index” can be calculated from the
addition of relevant age-related health variables such as symptoms, signs, abnormal laboratory values, disease
states, and disabilities [72].
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rates among fast walkers. Other studies have shown that the relationship between BP
and both mortality and adverse health outcomes could be modified by poor health,
such as physical and mental impairment [45, 48]. In the two previously mentioned
RCTs, HYVET and SPRINT, post hoc analyses however suggested that frailty does not
modify the benefit of anti-hypertensive treatment [39, 60].
The modification of the association between BP and health outcomes in case of frailty
or poor health may be explained by physiological reasons. Low BP in old and frail indi-
viduals might indeed cause hypo-perfusion of vital organs and accelerate physical and
mental decline [11], a state of physiological weakness, which is often worsened by the
presence of polypharmacy and comorbidity [10, 53]. Some authors suggest that the
presence of frailty or other indicators of poor health might be an argument for depre-
scribing antihypertensive treatments (Table 5) [10, 24].
Second, the association of a lower BP with worse health outcomes in cohort studies
may be due to confounding and reverse causality (Fig. 3). On the one hand, the associ-
ation between BP and any adverse health outcomes may be confounded by some unmeas-
ured factors. On the other hand, in a case of reverse causality, some conditions, which
can be initially caused by high BP, evolve to become the cause of low BP. For example,
high BP is a cause of heart failure [61], but in an advanced stage, heart failure becomes
the cause of a lower BP. In this case, there is an association between low BP and the con-
dition, as well as between low BP and mortality, but both these associations are the result
of a reverse causality. This situation is frequent in circumstances of end-of-life care [42].
Finally, the selection of relatively healthy patients in randomized trials compared with co-
horts may be a third explanation of the discrepancies between RCTs and cohort studies
[10]. Post-randomization confounding may also bias results of RCTs [62].
To disentangle these complex controversies on the association between BP and
health outcomes among older adults, hypertension trials targeting specifically frail or
multimorbid older adults are needed.
International guidelines for hypertension management in older adults
International guidelines about screening for and treatment of hypertension are mainly
targeting middle-aged adults (40–60 years). In line with the lack of strong evidence on the
most adequate way of managing hypertension in older adults, especially over 80 years of
age, there are no firm and consistent recommendations for this population (Table 6).
Table 5 Deprescribing antihypertensive treatment
Definition of deprescribing
Deprescribing can be defined as a systematic process of gradually lessening or stopping drugs with the aim to
reduce polypharmacy and improve patient outcomes. This process implies the identification of drugs that are
suspected to induce no benefit, or which potentially cause more harm than benefit for the patient.
Polypharmacy is common in older adults, and they are especially vulnerable to drug-related adverse events
[73]. Deprescribing is therefore particularly relevant in older adults.
Deprescribing antihypertensive treatment in older adults
Some data on antihypertensive treatment withdrawal exist showing that among well-selected older adults [74],
a relevant proportion of patients stay normotensive [75, 76], with minor withdrawal-associated risks [77] and
potentially beneficial effects on health [78]. Accordingly, a recent Canadian Guideline, specifically addressing BP
management in frail older adults, recommends to generally prescribe no more than two antihypertensive
medications and to reduce antihypertensive treatment when systolic BP is below 140 mmHg [79]. A recent
Cochrane review concluded that the effect of deprescribing was uncertain, with however no increase in mortality
among participants allocated to withdrawing from antihypertensive therapy [80].
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The US Preventive Services Task Force (USPSTF) 2015 guidelines recommend screening
for high BP among all adults aged 18 years or more [9]. The USPSTF does however not give
any specific recommendation for older adults regarding screening and BP measurement.
The European Society of Hypertension and the European Society of Cardiology (ESH/ESC)
2013 guidelines recommend out-of-office BP measurement in older adults to search for
orthostatic hypotension [8]. Other international guidelines do not give any specific recom-
mendations related to screening for hypertension among older adults [6–8] (Table 6).
Most guidelines recommend higher BP targets among older adults compared with
middle-aged adults [6–9]. Further, some of these guidelines recommend taking into ac-
count health status to set the targeted BP [6, 8]. The USPSTF 2015 guidelines and the
Eighth Joint National Committee (JNC 8) 2014 guidelines recommend targeting 150/
90 mmHg from age 60 years, but they mention that, according to some expert opinion,
140/90 mmHg can be targeted, as in younger adults [7, 9]. The UK National Institute
for Health and Care Excellence (NICE) 2011 guidelines recommend targeting 150/
90 mmHg from age 80 years, although 140/90 mmHg can be targeted among patients
without comorbidities [6]. The ESH/ESC guidelines 2013 recommend targeting an SBP <
140 mmHg in fit older adults up to 80 years of age and tailoring BP target according to in-
dividual tolerability in frail patients. Above 80 years of age, for patients in good physical
and mental condition, the ESH/ESC guidelines 2013 recommend targeting an SBP of
140–150 mmHg. For frail patients, the decision whether or not to treat has to be evalu-
ated by the physician, with a close monitoring of clinical effects of treatment [8].
The recent American College of Cardiology (ACC)/American Heart Association (AHA)
guidelines 2017 recommend a more aggressive treatment compared with other guidelines
[15]. The BP threshold to define hypertension was lowered to 130/80 mmHg, including for
patients over 80 years of age [15]. However, a close BP monitoring in older persons with high
comorbidity is recommended. This major change in the definition of hypertension is mainly
based on the results from the SPRINT trial [39]. These new ACC/AHA guidelines received
critiques from experts, questioning SPRINT’s methodology [63] and its generalizability [64].
Some experts consider that these guidelines downplay the adverse effects of antihyperten-
sive treatment, such as falls due to hypotension [65] and the risk for overtreatment and
polypharmacy [10, 66], especially in frail oldest-old patients [65]. In reaction, some experts
have developed their own guidelines with more conservative treatment recommendations
accounting for detrimental effects of low BP reported in cohort studies [67].
In summary, while international guidelines give clear recommendations about screening
for and treatment of hypertension in middle-aged adults, the recommendations in older
adults are much less clear, with large inconsistencies across different guidelines. This
Fig. 3 The hypothetical causal relationship between blood pressure (BP) and related adverse health outcomes
or mortality according to different scenarios is depicted in these graphs. (I) Usually, BP has a causal effect on
adverse health outcomes (O) and death (D). (II) The relationship can be confounded by unmeasured factors (C),
which have an effect on both BP and the risk of adverse health outcomes. (III) In a situation of reverse causality,
some conditions, which can be initially caused by high BP, evolve to become the cause of low BP
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reflects the lack of clear evidence on the risks and benefits of BP treatment and on the
optimal BP targets in older adults, especially for the frail and oldest-old patients.
Conclusion
Due to population aging, hypertension in older adults is a major and growing burden for
the health care system. Screening and treatment of hypertension in older adults, and espe-
cially in the oldest-old, is still a matter of intense debate notably due to the lack of high
quality evidence. Several important research questions have still to be addressed (Table 7),
especially about the relationship between frailty, multimorbidity, BP, and associated health
outcomes. While screening and treatment strategies accounting for general health status or
frailty are appealing, it raises the question of how to assess these clinical features with confi-
dence [56]. More broadly, various screening and treatment strategies should be evaluated
and compared with a population-based approach aiming to find the most appropriate way
of managing hypertension in older adults.
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Table 7 Challenges and areas for research about screening and treatment of hypertension among
older adults
1. How to screen for hypertension among older adults? At what frequency? In which setting? Universal
vs targeted screening?
2. What are the benefits and harms of lowering BP among older adults? What is the effect notably on
the quality of life?
3. What are the characteristics of the oldest-old whose high BP is associated with favorable health outcomes?
4. What is the relationship between frailty and BP, and what are the consequences of this relationship on the
prescription of treatment?
5. Can some factors (frailty, multimorbidity, polypharmacy, orthostatic hypotension) in older age be an
argument for deprescribing of antihypertensive drugs?
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